Standout Papers

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma 2010 2026 2015 2020 2.6k
  1. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma (2010)
    Keith T. Flaherty, Igor Puzanov et al. New England Journal of Medicine
  2. Vemurafenib: the first drug approved for BRAF-mutant cancer (2012)
    Gideon Bollag, James Tsai et al. Nature Reviews Drug Discovery
  3. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer (2015)
    Scott Kopetz, Jayesh Desai et al. Journal of Clinical Oncology
  4. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study (2015)
    Nicholas Butowski, Howard Colman et al. Neuro-Oncology

Immediate Impact

9 by Nobel laureates 24 from Science/Nature 71 standout
Sub-graph 1 of 18

Citing Papers

Targeting KRAS in cancer
2024 Standout
Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy
2023 Standout
5 intermediate papers

Works of K. B. Nolop being referenced

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
2015 Standout
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
2015 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
K. B. Nolop 3543 1504 3298 63 7.2k
Ronit Simantov 5436 4224 3293 87 11.0k
Olivier Kocher 4598 2928 2828 93 9.2k
Jeanette M. Wood 3741 803 2003 104 7.5k
Ron Bose 3491 1241 3062 93 6.6k
Violeta Serra 4096 1571 2987 91 7.3k
Gary C. Chamness 4806 1181 5649 95 11.1k
Stephen F. Madden 4721 1002 2131 160 8.0k
Vladimir Lazar 4011 933 2103 133 7.3k
Dilip D. Giri 2918 689 2865 94 6.8k
Wolter J. Mooi 5695 2570 4485 111 11.8k

All Works

Loading papers...

Rankless by CCL
2026